The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs.

[1]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Y. Ikada,et al.  Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[3]  A. Skubitz,et al.  Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil™) , 1998, Anti-cancer drugs.

[4]  J. Szebeni,et al.  The interaction of liposomes with the complement system. , 1998, Critical reviews in therapeutic drug carrier systems.

[5]  J. V. D. van der Want,et al.  Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat , 1997, Hepatology.

[6]  M. Bally,et al.  Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). , 1997, The Journal of pharmacology and experimental therapeutics.

[7]  H. Harashima,et al.  Kinetic study on the optimization of tumor delivery of antitumor agents by liposomes: Simulation study based on the physiological modeling. , 1997 .

[8]  D. Devine,et al.  The role of immunoproteins in the survival of liposomes in the circulation. , 1997, Critical reviews in therapeutic drug carrier systems.

[9]  H. Tsukada,et al.  In vivo trafficking of long-circulating liposomes in tumour-bearing mice determined by positron emission tomography. , 1996, Biopharmaceutics & drug disposition.

[10]  H. Harashima,et al.  Liposomal targeting and drug delivery: kinetic consideration , 1996 .

[11]  B. Tromberg,et al.  Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. , 1996, Cancer research.

[12]  Y. Kawai,et al.  Is control of distribution of liposomes between tumors and bone marrow possible? , 1996, Biochimica et biophysica acta.

[13]  Y. Koyanagi,et al.  Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy , 1996 .

[14]  D. Tzemach,et al.  Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. , 1996, Journal of drug targeting.

[15]  K. Maruyama,et al.  Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethylene glycol) , 1995 .

[16]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[17]  H. Tsukada,et al.  Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography. , 1995, Biochimica et biophysica acta.

[18]  H. Harashima,et al.  Effects of the size and fluidity of liposomes on their accumulation in tumors: A presumption of their interaction with tumors , 1995 .

[19]  H. Kiwada,et al.  Effect of vesicle size on in vivo release of daunorubicin from hydrogenated egg phosphatidylcholine-based liposomes into blood circulation. , 1995, Biological & pharmaceutical bulletin.

[20]  R. Perez-soler,et al.  Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non‐cross‐resistant anthracycline annamycin incorporated in liposomes , 1995, International journal of cancer.

[21]  K. Higashi,et al.  Effects of sialic acid derivative on long circulation time and tumor concentration of liposomes , 1995 .

[22]  H. Harashima,et al.  Size dependent liposome degradation in blood: in vivo/in vitro correlation by kinetic modeling. , 1995, Journal of drug targeting.

[23]  N. Oku,et al.  Therapeutic effect of adriamycin encapsulated in long‐circulating liposomes on meth‐a‐sarcoma‐bearing mice , 1994, International journal of cancer.

[24]  H. Kiwada,et al.  Effects of fluidity and vesicle size on antitumor activity and myelosuppressive activity of liposomes loaded with daunorubicin. , 1994, Biological & pharmaceutical bulletin.

[25]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[26]  D. Devine,et al.  Liposome-complement interactions in rat serum: implications for liposome survival studies. , 1994, Biochimica et biophysica acta.

[27]  N. Van Rooijen,et al.  Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. , 1994, Biochimica et biophysica acta.

[28]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[29]  M. Newman,et al.  Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®) , 1994 .

[30]  M. Ross,et al.  Daunoxome® Treatment of Solid Tumors: Preclinical and Clinical Investigations , 1994 .

[31]  N. Oku,et al.  Long-circulating liposomes. , 1994, Critical reviews in therapeutic drug carrier systems.

[32]  D Needham,et al.  Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. , 1993, Cancer research.

[33]  F. Martin,et al.  Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. , 1993, The American journal of pathology.

[34]  D. Friend,et al.  Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. , 1992, Cancer research.

[35]  K. Maruyama,et al.  Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). , 1992, Biochimica et biophysica acta.

[36]  P. Cullis,et al.  Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.

[37]  Y. Barenholz,et al.  In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. , 1992, Biochimica et biophysica acta.

[38]  N. Oku,et al.  Tumor accumulation of novel RES-avoiding liposomes. , 1992, Biochimica et biophysica acta.

[39]  D. Coulter,et al.  Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. , 1992, Cancer research.

[40]  K. Matthay,et al.  Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.

[41]  L. Huang,et al.  Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. , 1992, Biochimica et biophysica acta.

[42]  A. Gabizon.  Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. , 1992, Cancer research.

[43]  A. Gabizon,et al.  The role of surface charge and hydrophilic groups on liposome clearance in vivo. , 1992, Biochimica et biophysica acta.

[44]  H M Patel,et al.  Serum opsonins and liposomes: their interaction and opsonophagocytosis. , 1992, Critical reviews in therapeutic drug carrier systems.

[45]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[46]  T. Allen,et al.  Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.

[47]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[48]  V. Torchilin,et al.  Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.

[49]  G Gregoriadis,et al.  Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. , 1991, Biochimica et biophysica acta.

[50]  G Blume,et al.  Liposomes for the sustained drug release in vivo. , 1990, Biochimica et biophysica acta.

[51]  F. Borek.  Liposomes in the therapy of infectious diseases and cancer: Lopez-Berestein, G. and Fidler, I.J. (Eds.), 500 pp. Alan R. Liss, New York, 1989. USD 96.00, ISBN 0-8451-2688-1 , 1990 .

[52]  A. Gabizon,et al.  Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. , 1990, Cancer research.

[53]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[54]  M. Bally,et al.  Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. , 1990, Cancer research.

[55]  Y. Barenholz,et al.  Preclinical and Clinical Experience with a Doxorubicin-Liposome Preparation , 1990 .

[56]  R K Jain,et al.  Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. , 1990, Journal of the National Cancer Institute.

[57]  N. Oku,et al.  1-O-Palmityl-D-glucuronate Endows Liposomes with Long Half-Life In Vivo , 1989 .

[58]  M. Bally,et al.  Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.

[59]  A. Gabizon,et al.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.

[60]  R. K. Zee-Cheng,et al.  Delivery of anticancer drugs. , 1989, Methods and findings in experimental and clinical pharmacology.

[61]  T. Allen,et al.  Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. , 1989, Biochimica et biophysica acta.

[62]  H. Maeda,et al.  Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.

[63]  A. Gabizon,et al.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[64]  T M Allen,et al.  Large unilamellar liposomes with low uptake into the reticuloendothelial system , 1987, FEBS letters.

[65]  J H Senior,et al.  Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.

[66]  R. Habbersett,et al.  Influence of vesicle size on complement-dependent immune damage to liposomes. , 1986, Biochimica et biophysica acta.

[67]  D. Papahadjopoulos,et al.  Gangliosides reduce leakage of aqueous-space markers from liposomes in the presence of human plasma. , 1985, Biochimica et biophysica acta.

[68]  E. Wisse,et al.  The liver sieve: Considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of disse , 1985, Hepatology.

[69]  G. Gregoriadis,et al.  Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. , 1985, Biochimica et biophysica acta.

[70]  M. Poznansky,et al.  Biological approaches to the controlled delivery of drugs: a critical review. , 1984, Pharmacological reviews.

[71]  P. Sunkara.  Novel approaches to cancer chemotherapy , 1984 .

[72]  G. Poste.  5 – Liposomes as a Drug Delivery System in Cancer Therapy , 1984 .

[73]  T. Allen,et al.  Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. , 1983, The Journal of pharmacology and experimental therapeutics.

[74]  C. Presant,et al.  Liposomal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. , 1983, Science.

[75]  G. Gregoriadis,et al.  Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. , 1982, Life sciences.

[76]  C. Hunt,et al.  Liposome disposition in vivo. III. Dose and vesicle-size effects. , 1981, Biochimica et biophysica acta.

[77]  R. Souhami,et al.  The effect of reticuloendothelial blockade on the blood clearance and tissue distribution of liposomes. , 1981, Biochimica et biophysica acta.

[78]  G. Gregoriadis,et al.  Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. , 1980, The Biochemical journal.

[79]  A. Hirano,et al.  Vascular structures in brain tumors. , 1975, Human pathology.

[80]  R L Juliano,et al.  The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. , 1975, Biochemical and biophysical research communications.

[81]  B. Warren.  The ultrastructure of the microcirculation at the advancing edge of Walker 256 carcinoma. , 1970, Microvascular research.